Mr. Suresh Subramanian, Senior Vice President & Head Branded Formulations, Biocon shares his views on how KRABEVA® can make a significant impact in the biosimilars space.
Biocon reported strong Q2FY17 results. Small Molecules, Biologics and Research Services businesses showed strong growth while it was a stand-out quarter for the Biologics business.
Part 2 – The potential financial benefits and better health outcomes from biosimilars use could spur their uptake in health systems globally.
Part 1 – Biosimilars can provide cost-effective, high quality alternatives to expensive reference biologics, thus improving access and expanding the patient base.